Eli Lilly Acquires Prevail Therapeutics

AbbVie Acquires Cerevel Therapeutics

December 6, 2023

Biotechnology

AbbVie Inc. acquired Cerevel Therapeutics for $45.00 per share, valuing Cerevel at approximately $8.7 billion, to bolster AbbVie's neuroscience pipeline. The deal adds Cerevel's clinical-stage assets—including emraclidine, tavapadon, CVL-354 and darigabat—and is intended to expand AbbVie's capabilities and commercial potential in psychiatric and neurological disorders.

Eli Lilly Acquires Adverum Biotechnologies

December 9, 2025

Biotechnology

Eli Lilly, through its wholly owned subsidiary Flying Tigers Acquisition Corporation, completed a tender offer to acquire Adverum Biotechnologies. Shareholders tendered approximately 64% of outstanding shares for $3.56 per share plus one contingent value right (CVR) per share (up to $8.91 aggregate upon milestone achievement); the parties expect to consummate the merger on December 9, 2025.

Innoviva Acquires La Jolla Pharmaceutical Company

July 11, 2022

Pharmaceuticals

Innoviva, Inc. completed a cash tender offer to acquire La Jolla Pharmaceutical Company for $6.23 per share, valuing the deal at an implied enterprise value of approximately $149 million. The acquisition adds La Jolla's marketed infectious disease and hospital products (GIAPREZA and XERAVA) to Innoviva's healthcare portfolio to expand its commercial footprint in anti-infectives and hospital therapeutics.

Eli Lilly Acquires Verve Therapeutics

July 25, 2025

Biotechnology

Eli Lilly and Company completed the acquisition of Verve Therapeutics, a Boston-based clinical-stage developer of one-time gene-editing therapies for cardiovascular disease. Lilly said the deal will integrate Verve's genetic-medicine programs into its cardiometabolic research to advance potential lifelong cardiovascular risk–reduction treatments.

Eli Lilly Acquires POINT Biopharma Global

December 27, 2023

Biotechnology

Eli Lilly and Company completed the acquisition of POINT Biopharma Global Inc. after a tender offer at $12.50 per share in cash, followed by a second-step merger and delisting of POINT's common stock. The transaction brings POINT's radioligand therapy pipeline and radiopharmaceutical capabilities into Lilly's oncology research and development efforts.

AbbVie to Acquire ImmunoGen for $10.1 Billion

November 30, 2023

Biotechnology

AbbVie has entered into a definitive agreement to acquire ImmunoGen for $31.26 per share in cash, valuing the company at approximately $10.1 billion. The deal gives AbbVie commercial rights to ELAHERE (mirvetuximab soravtansine-gynx) and ImmunoGen's ADC pipeline, expanding AbbVie's oncology capabilities; the transaction is expected to close in mid-2024 subject to shareholder and regulatory approvals.